Abstract
Clinical Effectiveness and Safety of Olprinone Combined with Qiliqiangxin Capsule for Severe Pulmonary Arterial Hypertension and Right Heart Failure
Department of Cardiology, Xiamen Hospital of Traditional Chinese Medicine, Siming, Xiamen 361009, China
Correspondence Address:
L. Chen, Department of Cardiology, Xiamen Hospital of Traditional Chinese Medicine, Siming, Xiamen 361009, China, E-mail: clf7008@163.com
The present research sets out to elucidate the clinical effectiveness and safety of olprinone combined with qiliqiangxin capsule in the treatment of severe pulmonary arterial hypertension complicated with right heart failure. 55 severe pulmonary arterial hypertension and right heart failure individuals admitted between April 2020 and April 2023 were selected and were assigned as control group (n=25) receiving olprinone treatment while the research group (n=30) received olprinone combined with qiliqiangxin capsules. The clinical effectiveness, safety (rash, chest pain, nausea, vomiting, dizziness, hypotension and tachycardia), echocardiography systolic pulmonary artery pressure, tricuspid annulus plane systolic excursion, right ventricular fractional area change, inferior vena cava collapse index, 6 min walking test and serum N-terminal pro-brain B-type natriuretic peptide were comparatively analyzed. The results showed an evidently higher overall effective rate and a comparable safety profile of the research group compared with the control group. The research group showed markedly reduced systolic pulmonary artery pressure and N-terminal pro-brain B-type natriuretic peptide levels, elevated tricuspid annulus plane systolic excursion, fractional area change, inferior vena cava collapse index and 6 min walking test after treatment, than the control group. Therefore, the combination of olprinone and qiliqiangxin capsule is effective and safe in the treatment of severe pulmonary arterial hypertension+right heart failure patients, which can significantly improve echocardiography results and patients’ exercise ability while exerting a significant inhibitory effect on serum N-terminal pro-brain B-type natriuretic peptide.
Full-Text | PDF